Theravance Biopharma annual ebitda
2012
2013
2014
2015
2016
2017
2018
Theravance Biopharma EBITDA Growth & History (TBPH)
Theravance Biopharma's calculated EBITDA was −$235.6M for fiscal 2018.
View full Theravance Biopharma company overviewTheravance Biopharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2018 | 2018-12-31 | −$235.6M | $20.5M | — |
| 2017 | 2017-12-31 | −$256.1M | −$78.7M | — |
| 2016 | 2016-12-31 | −$177.3M | $1.6M | — |
| 2015 | 2015-12-31 | −$178.9M | $50.4M | — |
| 2014 | 2014-12-31 | −$229.3M | −$75.6M | — |
| 2013 | 2013-12-31 | −$153.6M | −$147.3M | — |
| 2012 | 2012-12-31 | −$6.3M | — | — |
Theravance Biopharma quarterly ebitda
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q1 2019 | 2019-03-31 | −$72.3M | −$8.4M | — |
| Q4 2018 | 2018-12-31 | −$61.8M | $16.4M | — |
| Q3 2018 | 2018-09-30 | −$61.8M | −$5.8M | — |
| Q2 2018 | 2018-06-30 | −$48.0M | $16.1M | — |
| Q1 2018 | 2018-03-31 | −$64.0M | −$6.2M | — |
| Q4 2017 | 2017-12-31 | −$78.2M | −$21.5M | — |
| Q3 2017 | 2017-09-30 | −$56.0M | −$23.3M | — |
| Q2 2017 | 2017-06-30 | −$64.1M | −$17.1M | — |
| Q1 2017 | 2017-03-31 | −$57.7M | −$16.8M | — |
| Q4 2016 | 2016-12-31 | −$56.7M | −$1.6M | — |
| Q3 2016 | 2016-09-30 | −$32.7M | $9.7M | — |
| Q2 2016 | 2016-06-30 | −$47.0M | −$2.5M | — |
| Q1 2016 | 2016-03-31 | −$40.9M | −$4.0M | — |
| Q4 2015 | 2015-12-31 | −$55.1M | $9.9M | — |
| Q3 2015 | 2015-09-30 | −$42.4M | $6.6M | — |
| Q2 2015 | 2015-06-30 | −$44.5M | $11.5M | — |
| Q1 2015 | 2015-03-31 | −$36.9M | $22.4M | — |
| Q4 2014 | 2014-12-31 | −$65.0M | −$24.5M | — |
| Q3 2014 | 2014-09-30 | −$49.0M | −$10.7M | — |
| Q2 2014 | 2014-06-30 | −$56.0M | — | — |
| Q1 2014 | 2014-03-31 | −$59.3M | — | — |
| Q3 2013 | 2013-09-30 | −$40.5M | — | — |
| Q2 2013 | 2013-06-30 | −$38.3M | — | — |
Theravance Biopharma ebitda trends
Over the last five reported fiscal years, Theravance Biopharma's ebitda decreased from −$153.6M to −$235.6M, a change of −$82.0M. The latest reported quarter, Q1 2019, shows −$72.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Theravance Biopharma filings at SEC.gov ↗